• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.960 -0.510 (-4.87%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,735,613
Open 10.49
Bid (Size) 9.750 (1,000)
Ask (Size) 9.990 (200)
Prev. Close 10.47
Today's Range 9.910 - 10.49
52wk Range 4.815 - 12.00
Shares Outstanding 133,976,538
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
October 14, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
October 08, 2026
From Vir Biotechnology, Inc.
Via Business Wire

Performance

52-Week Range 17.0% below 52-week high
9.960
4.8252W Low 12.0052W High
1 Week 15.7% below 1-week high
9.911W Low 11.821W High

Vir Biotechnology, Inc. - Common Stock (VIR) traded between $4.82 and $12.00 over the past 52 weeks and last traded at $9.96, 17.0% below its 52-week high. Over the past week it ranged between $9.91 and $11.82.

Past 12 Months
-11.9%
-8.8%
+7.9%
-10.2%
+67.7%
+72.3%
1W -$1.34
1M -$0.96
3M +$0.73
6M -$1.13
YTD +$4.02
1Y +$4.18

VIR was +72.3% over the past year, -10.2% over six months, +67.7% year to date, -11.9% in the last week.

12 Months vs Market
VIR
+72.3%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months VIR returned +72.3% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.90× 3-mo avg
Today 1,735,613 3-mo avg 1.9M
1W
1.8M
1M
2.3M
3M
1.9M
6M
1.9M
YTD
2.4M
1Y
2.2M

VIR most recently traded 1,735,613 shares against a 3-month average daily volume of 1.9M.

More News

Read More
News headline image
Vir Biotechnology Appoints David Liu as Chief Medical Officer
October 07, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
October 05, 2026
From Vir Biotechnology, Inc.
Via Business Wire
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration ↗
August 05, 2026
Via Chartmill
7 Bull Flag Setups Found With the ChartMill Stock Screener ↗
April 28, 2026
Via Chartmill
News headline image
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
October 01, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 05, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Chief Financial Officer Transition
July 24, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
July 22, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
June 10, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
May 23, 2026
Via The Motley Fool
News headline image
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
May 18, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Energy Vault Stock Has Surged 500%. One Major Holder Just Sold 3 Million Shares ↗
May 18, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗
May 17, 2026
Via The Motley Fool
News headline image
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
May 14, 2026
From World Street Intelligence
Via GlobeNewswire
News headline image
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors. ↗
May 09, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vir (VIR) Q1 2026 Earnings Call Transcript ↗
May 06, 2026
Via The Motley Fool
Topics Earnings
News headline image
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 06, 2026
From Vir Biotechnology, Inc.
Via Business Wire
News headline image
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
May 05, 2026
From Vir Biotechnology
Via Business Wire
News headline image
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
April 23, 2026
From Vir Biotechnology, Inc.
Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?
Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Vir Biotechnology, Inc. - Common Stock trade on?
Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?
The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market
What is the current price of Vir Biotechnology, Inc. - Common Stock?
The current price of Vir Biotechnology, Inc. - Common Stock is 9.960
When was Vir Biotechnology, Inc. - Common Stock last traded?
The last trade of Vir Biotechnology, Inc. - Common Stock was at 10/16/26 04:00 PM ET
What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?
The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.33B
How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?
Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap